Anika to Participate in Upcoming November 2023 Investor Conferences

2023-11-07

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences: The Stephens Annual Investment Conference at the Grand Hyatt, Nashville, TN, on Wednesday, November 15, 2023. The Company will host a live presentation starting at 8:00 a.m. CT/9:00 a.m. ET. Management will be hosting 1x1 investor meetings the same day. The Piper Sandler 35th Annual Healthcare Conference at the Lotte New York Palace on Wednesday, November 29, 2023. The Company will host a live presentation starting at 2:50 p.m. ET. Management will be hosting 1x1 investor meetings the same day. Webcasts of all events will be available in the Investor Relations section of Anika’s website, . An archive of the all the presentations will also be available on the website. About Anika Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit . ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc. For Investor Inquiries: Anika Therapeutics, Inc. Mark Namaroff, 781-457-9287 Vice President, Investor Relations, ESG and Corporate Communications investorrelations@anika.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构